-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Image: Marwan Fakih, MD, is the lead author of The Lancet Oncology Research and the co-director of the gastrointestinal cancer project in the "City of Hope" cancer research and treatment organization based near Los Angeles
The City of Hope, a world-renowned cancer research and treatment organization in California, today announced the results of a phase II clinical trial, demonstrating that sotorasib monotherapy has good anti-tumor effects in severely treated patients with advanced colorectal cancer Activity and good yield
According to the Centers for Disease Control and Prevention (Centers for Disease Control and Prevention), colorectal cancer is the third most common cancer in the United States and the second leading cause of cancer deaths
The part of the study focused on colorectal cancer patients carrying the KRAS G12C mutation, accounting for about 4% of colorectal cancer patients
"For these chemotherapy-resistant populations, the results of this study exceed the historical benefits of approved third and fourth-line treatments for advanced colorectal cancer," said Professor Marwan Fakih, the article’s lead study author and "City of Hope "The head of the joint gastrointestinal cancer project
Although the remission rate of the study did not meet expectations, the ongoing single-arm Phase II CodeBreaK 100 trial shows (single-arm Phase II refers to a single-group tumor trial with no controls, targeting tumors that are rarely likely to shrink without external intervention), Among the 62 patients included, the objective response rate was 9.
"These data from the Phase 2 CodeBreaK 100 show that sotorasib has encouraging clinical activity and positive benefits in heavily pretreated patients with advanced colorectal cancer, and the response rate exceeds the current standard of care and treatment
Fakih said that currently, patients with recurrent and metastatic colorectal cancer receive approved treatment options (such as trifluridine and regorafenib) with a total effective rate of between 1-4%
"We are now working to improve the efficacy of sotorasib in combination with panitumumab, thereby more completely blocking the EGFR pathway and improving tumor prognosis
# # #
